KPTI · Karyopharm Therapeutics Inc
United States · RS rating 1 · As of 2026-11-03
| Price | 0.09 USD |
|---|---|
| 1-day change | -21.2% |
| RS rating (overall / 1M / 3M / 12M) | 1 / 1 / 1 / 2 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 34 / 2 / 15 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -49.5% |
| Sales growth Q/Q | -22.6% |
| Distance from 52-week high | +99.2% |
| Market cap (USD) | $197.3M |